RECRUITING

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Talk to us

Conditions

Non-small Cell Lung CancerNon-squamousPDL-1 ≥ 1%

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Official Title

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Quick Facts

Study Start:2024-10-07
Study Completion:2033-11-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06561386

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Study Connect www.BMSStudyConnect.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site#
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Local Institution - 0368
Tucson, Arizona, 85723
United States
Local Institution - 0111
Los Angeles, California, 90404
United States
Local Institution - 0112
Los Angeles, California, 90404
United States
Local Institution - 0304
Sacramento, California, 95817
United States
Local Institution - 0159
San Francisco, California, 94115
United States
Local Institution - 0206
Miami, Florida, 33136
United States
Local Institution - 0162
Pembroke Pines, Florida, 33028
United States
Local Institution - 0358
Saint Petersburg, Florida, 33705
United States
Local Institution - 0360
West Palm Beach, Florida, 33401
United States
Saint Elizabeth Medical Center Edgewood
Edgewood, Kentucky, 41017
United States
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi, 39401-7233
United States
Bozeman Health Deaconess Hospital
Bozeman, Montana, 59715
United States
Renown Regional Medical Center
Reno, Nevada, 89502
United States
Local Institution - 0346
Paterson, New Jersey, 07503
United States
Local Institution - 0381
Albuquerque, New Mexico, 87108
United States
Local Institution - 0357
Bronx, New York, 10468
United States
Local Institution - 0356
Hawthorne, New York, 10532
United States
Local Institution - 0392
New York, New York, 10010
United States
Local Institution - 0380
Northport, New York, 11768
United States
Local Institution - 0325
Rochester, New York, 14642
United States
Local Institution - 0324
Syracuse, New York, 13210
United States
Local Institution - 0369
Canton, Ohio, 44708
United States
Local Institution - 0199
Cleveland, Ohio, 44106
United States
Local Institution - 0366
Massillon, Ohio, 44646
United States
Local Institution - 0272
Lancaster, Pennsylvania, 17602
United States
Local Institution - 0359
Abilene, Texas, 79606-5208
United States
Local Institution - 0305
Harlingen, Texas, 78550
United States
Local Institution - 0378
Houston, Texas, 77030
United States
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center
Tyler, Texas, 75701
United States
Local Institution - 0302
Salt Lake City, Utah, 84112
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-07
Study Completion Date2033-11-11

Study Record Updates

Study Start Date2024-10-07
Study Completion Date2033-11-11

Terms related to this study

Keywords Provided by Researchers

  • Non-squamous
  • PDL-1 ≥ 1%

Additional Relevant MeSH Terms

  • Non-small Cell Lung Cancer